莫西沙星联合阿奇霉素治疗支原体肺炎80例临床疗效观察

Clinical observation of moxifioxacin combined with azithromycin in treating 80 patients with mycoplasma pneumonia

目的评价莫西沙星联合阿奇霉素治疗支原体肺炎的临床有效性及安全性。方法将80例支原体肺炎患者随机分为对照组和治疗组，两组均口服阿奇霉素治疗，治疗组在上述基础上同时口服莫西沙星，观察两组的临床指标、疗效及不良反应等情况的变化。结果经治疗后，治疗组临床症状、体征的改善时间显著优于对照组（P〈0．01）。治疗组总有效率为92．5％，痰培养细菌转阴率为90．0％；对照组总有效率为75．0％，痰培养细菌转阴率为70．0％，两组之间差异有统计学意义（P〈0．05）。同时，治疗组的不良反应发生率为10．0％，对照组不良反应发生率为7．5％，两组之间差异无统计学意义（P〉0．05）。结论莫西沙星与阿奇霉素联合应用较单一使用阿奇霉素有更好的临床疗效，且未增加不良反应发生率，可在临床进一步推广。

Objective To evaluate the clinical efficacy and safety of the treatment of moxifloxacin combined with azithromyein on mycoplasma pneumonia. Methods 80 patients with mycoplasma pneumonia were randomly divided into control group and treatment group. The cases in both groups were treated with azithromycin and at the same time the treatment group was given moxifloxacin. The changes of clinical parameters, efficacy and adverse reactions were observed. Results After treatment, the time of clinical improvement in treatment group was significantly better than that in control group （ P 〈0.01）. The total effective rate in treatment group was 92.5% and the bacteria negative rate of sputum culture was 90.0% in treated group. While in control group, the total effective rate was 75.0%, and the bacteria negative rate was 70.0%, the difference between two groups was statistically significant （P 〈0.05）. Meanwhile, the adverse reaction rate in treatment group was 10.0%, and it was 7.5% in control group, there was no significant difference between the two groups （P 〉 0. 05）. Conclusions Moxifloxaein combined with azithromyein treated in mycoplasma pneumonia has a better clinical efficacy compared with single-use azithromyein, which does not increase the incidence of adverse reactions and can be further promoted in clinical.